Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

REVASC-PAD: Begrænset Vaskulær Træning for Perifer Arteriel Sygdom - En Gennemførlighedsundersøgelse ved University of Tennessee Medical Center (REVASC-PAD)

REVASC-PAD: Begrænset Vaskulær Træning for Perifer Arteriel Sygdom - En Gennemførlighedsundersøgelse på University of Tennessee Medical Center

The purpose of this study is to evaluate the effects of Blood Flow Restriction (BFR) training on walking function, health-related quality of life, and safety among adults with Peripheral Arterial Disease (PAD).

The main aims of the study are:

  1. Evaluate change in walking function among patients with PAD undergoing BFR training. The investigators will assess change in Six-Minute Walk Test (6MWT) distance from baseline to post-intervention and 3-month follow-up to compare functional improvements between the BFR group and the two control groups
  2. Assess changes in health-related quality of life among patients with PAD undergoing BFR training. The investigators will use the EuroQol 5-Dimension 5-Level (EQ-5D-5L) scale to evaluate quality-of-life changes from baseline to post-intervention and 3-month follow-up across all study arms
  3. Evaluate the safety and feasibility of a supervised BFR training program for patients with PAD. The investigators will compare adverse event (AE) and serious adverse event (SAE) rates across study arms, while also monitoring sessional ratings of perceived exertion (RPE), dyspnea, and claudication pain as indicators of symptom response and exercise tolerance. Feasibility will be assessed through enrollment success, intervention adherence, and retention rates across groups

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

81

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Tiffany Johnson, Study Coordinator
  • Telefonnummer: +1865-305-4682
  • E-mail: thjohnson@utmck.edu

Studiesteder

    • Tennessee
      • Knoxville, Tennessee, Forenede Stater, 37920
        • Rekruttering
        • University of Tennessee Medical Center
        • Ledende efterforsker:
          • Morgan Randall, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. 18 years of age or older
  2. Diagnosed peripheral arterial disease with stable claudication (symptomatic presentation unchanged for 6 months)
  3. Ankle-brachial index (ABI) between 0.4 and 0.9.
  4. Eligible referral to cardiovascular or pulmonary rehabilitation
  5. Prior revascularization permitted if symptoms are stable and other criteria are met

Exclusion Criteria:

  1. Recent change in resting ECG suggesting significant ischemia, recent myocardial infarction (within 2 weeks), or another acute cardiac event
  2. Unstable angina
  3. Uncontrolled cardiac arrhythmias
  4. Symptomatic severe aortic stenosis or other significant valvular disease
  5. Decompensated symptomatic heart failure
  6. Acute pulmonary embolism or infarction
  7. Acute noncardiac disorder likely to interfere with or be worsened by exercise (e.g., infection, thyrotoxicosis)
  8. Acute myocarditis or pericarditis
  9. Acute thrombophlebitis
  10. Physical disability precluding safe or adequate exercise performance
  11. Significant electrolyte abnormalities
  12. Clinically significant tachyarrhythmias or bradyarrhythmias
  13. High-degree atrioventricular block
  14. Atrial fibrillation with uncontrolled ventricular response
  15. Hypertrophic obstructive cardiomyopathy with resting left ventricular outflow gradient of >25 mmHg
  16. Known active aortic dissection
  17. Severe resting arterial hypertension (SBP>200mmHg or DBP >110 mmHg)
  18. Mental impairment preventing cooperation with study procedures
  19. Current pregnancy
  20. Moderate to severe peripheral neuropathy
  21. Open wounds or compromised skin near BFR cuff site
  22. Active DVT or thromboembolic event within the past year

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Blood Flow Restriction (BFR) Training

Participants perform supervised lower-body resistance training using pneumatic cuffs (Smart Cuff Pro or equivalent) applied to the proximal thighs. Cuffs are inflated to 60-80% of the participant's measured arterial occlusion pressure (AOP). Pressure is increased at Weeks 5 and 9 based on tolerance. Cuff inflation will not exceed 80% of limb occlusion pressure. Cuffs will be immediately deflated if participants' vitals suggest poor tolerance.

All BFR resistance sessions will include two standardized lower-extremity exercises: seated calf raises and standing calf raises. Each session will follow this protocol:

  1. 1 set of 30 repetitions, followed by 3 sets of 15 repetitions
  2. 30 seconds rest between sets, with the cuff remaining inflated
  3. Load set at 20-35% of 1RM
  4. Cuff deflated immediately after the fourth set or after 6 continuous minutes of inflation, whichever comes first
Aktiv komparator: Low-Load Traditional Resistance Training (LL-RT)

Participants perform the same two calf exercises (seated and standing calf raises) without BFR cuffs. If participants demonstrate the ability to complete all prescribed repetitions without undue strain, planned load progressions of approximately 5-10% 1RM will be introduced at Weeks 5 and 9. Repetitions and sets will remain fixed to match the BFR protocol.

Two resistance exercises (seated and standing calf raises) using the same repetition structure

  1. 1 set of 30 repetitions, followed by 3 sets of 15 repetitions
  2. Load set at 20-35% of 1RM
  3. 30 seconds rest between sets
  4. No BFR cuffs will be used
Aktiv komparator: High-Load Traditional Resistance Training (HL-RT)

Participants in this group will perform seated and standing calf raises following a more conventional strength training model. Similar to the other groups, if participants can complete their prescribed workload without excessive strain, two planned load progressions (5-10% 1RM) will be applied at Weeks 5 and 9. Repetitions and sets will remain fixed to preserve consistency in training structure across groups. This group serves as a benchmark for conventional resistance training in clinical and musculoskeletal rehabilitation populations.

Each session includes:

  1. 3 sets of 8-12 repetitions
  2. Load set at 60-70% of 1RM
  3. Rest periods of 60-90 seconds between sets
  4. No BFR cuffs will be used

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Walking Function
Tidsramme: Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)

Change in walking distance measured by the Six-Minute Walk Test (6MWT) from baseline to end of intervention and 3-month follow-up visit.

Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)
Quality of Life (QoL) (1)
Tidsramme: Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)

Change in health-related quality of life as assessed by EuroQol 5-Dimension 5-Level (EQ-5D-5L) from baseline to post-intervention and 3-month follow-up

Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)
Quality of Life (QoL) (2)
Tidsramme: Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)

Change in depressive symptoms as assessed by Patient Health Questionnaire-9 (PHQ-9) from baseline to post-intervention and 3-month follow-up

Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)
Quality of Life (QoL) (3)
Tidsramme: Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)

Change in self-reported walking function and symptom burden assessed by using REVASC-PAD Walking Questionnaire from baseline to post-intervention and 3-month follow-up

Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Claudication Onset Time (COT) during 6MWT
Tidsramme: Baseline, post-intervention (8 to 12 weeks), and 3 months post-intervention

Time to onset of claudication symptoms during 6MWT at baseline, post-intervention, and 3-month follow-up

Baseline, post-intervention (8 to 12 weeks), and 3 months post-intervention
Ratings of Perceived Exertion (RPE), Dyspnea, and Claudication Pain
Tidsramme: Multiple assessments from Visit 2 through end of intervention (approximately 8 to 12 weeks)

Session-based self-reported symptom ratings collected at each supervised exercise session from Visit 2 to end of intervention (approximately 8 to 12 weeks). These ratings assess exercise tolerance and symptom burden during blood flow restriction training.

Multiple assessments from Visit 2 through end of intervention (approximately 8 to 12 weeks)
Adverse Event (AE) and Serious Adverse Event (SAE) Rates
Tidsramme: Baseline to 3-month follow-up

Number and rate of adverse events and serious adverse events occurring during the study period.

Baseline to 3-month follow-up
Enrollment, Retention, and Adherence Rates
Tidsramme: Baseline to 3-month follow-up

Rates of successful enrollment, participant retention at post-intervention and 3-month follow-up, and adherence to prescribed exercise sessions

Baseline to 3-month follow-up

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

27. april 2026

Primær færdiggørelse (Anslået)

27. april 2027

Studieafslutning (Anslået)

27. april 2027

Datoer for studieregistrering

Først indsendt

24. oktober 2025

Først indsendt, der opfyldte QC-kriterier

28. oktober 2025

Først opslået (Faktiske)

31. oktober 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

4. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 5460
  • Institutional Review Board (Anden identifikator: The University of Tennessee Health Science Center)

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .